INT241498

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 6.46
Pain Relevance 0.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Abl1) DNA binding (Abl1) cytoplasm (Abl1)
cytosol (Abl1) nucleolus (Abl1) cell adhesion (Abl1)
Abl1 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 4 93.00 High High
Potency 20 80.44 Quite High
Paracetamol 5 69.88 Quite High
rheumatoid arthritis 2 41.84 Quite Low
palliative 4 40.48 Quite Low
Pain 6 27.64 Quite Low
Bioavailability 4 27.24 Quite Low
corticosteroid 7 16.64 Low Low
adenocard 2 9.32 Low Low
antagonist 1 8.64 Low Low
Disease Link Frequency Relevance Heat
Myeloproliferative Disorder 33 99.72 Very High Very High Very High
Leukemia 74 96.92 Very High Very High Very High
Myeloid Leukemia 363 96.52 Very High Very High Very High
Fever 9 94.68 High High
Apoptosis 12 94.08 High High
Colitis 2 93.88 High High
Cytomegalovirus Infection 2 93.00 High High
Pneumonia 3 92.80 High High
Pleural Effusion 41 92.28 High High
Cancer 149 90.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
One major effect of the JAK2 activation by Bcr-Abl is the increase in c-Myc expression (Xie et al 2002) which is important for leukemia induction (Sawyers et al 1992).
Regulation (effect) of Abl associated with leukemia
1) Confidence 0.32 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.53 Pain Relevance 0
P-loop mutated BCR-ABL is generally sensitive or intermediately sensitive to dasatinib, with IC50 values falling in the range of 1 to 11 nM [11].
Regulation (sensitive) of ABL
2) Confidence 0.26 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2567340 Disease Relevance 0.33 Pain Relevance 0.04
The two most common affect the BCR-ABL gene itself, namely mutations in its tyrosine kinase domain and overexpression of the Bcr-Abl protein due to amplification of the BCR-ABL gene.58–62 The third mechanism is represented by phenomena which lead to Bcr-Abl-independent resistance.
Regulation (affect) of Abl
3) Confidence 0.18 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886328 Disease Relevance 0.94 Pain Relevance 0.03
By definition, the other MPDs lack the BCR-ABL as a therapeutic target.
Regulation (target) of ABL associated with myeloproliferative disorder
4) Confidence 0.13 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721304 Disease Relevance 1.36 Pain Relevance 0
The two most common affect the BCR-ABL gene itself, namely mutations in its tyrosine kinase domain and overexpression of the Bcr-Abl protein due to amplification of the BCR-ABL gene.58–62 The third mechanism is represented by phenomena which lead to Bcr-Abl-independent resistance.
Regulation (affect) of ABL
5) Confidence 0.11 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886328 Disease Relevance 0.94 Pain Relevance 0.03
Imatinib is specific for the TK domain in abl (the Abelson proto-oncogene), c-kit and PDGF-R.
Regulation (specific) of abl
6) Confidence 0.07 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886340 Disease Relevance 0.61 Pain Relevance 0
Druker and colleagues first recognized the BCR-ABL protein to be an excellent target for imatinib as the BCR-ABL mutation is present in the vast majority of patients with CML.
Regulation (target) of ABL associated with myeloid leukemia
7) Confidence 0.06 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503651 Disease Relevance 0.64 Pain Relevance 0.07
The function of BCR-ABL has allowed the design and development of imatinib, a small-molecule kinase inhibitor that targets PDGFR, c-Kit, and ABL kinases (Deininger et al 2005).
Regulation (targets) of ABL
8) Confidence 0.06 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994207 Disease Relevance 1.11 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox